| Identification | Back Directory | [Name]
Benzamide, N-(4-ethoxyphenyl)-4-(2H-tetrazol-5-yl)- | [CAS]
1026587-58-5 | [Synonyms]
Xanthine oxidoreductase-IN-4
N-(4-Ethoxyphenyl)-4-(1H-tetrazol-5-yl)benzamide
Benzamide, N-(4-ethoxyphenyl)-4-(2H-tetrazol-5-yl)- | [Molecular Formula]
C16H15N5O2 | [MOL File]
1026587-58-5.mol | [Molecular Weight]
309.32 |
| Hazard Information | Back Directory | [Uses]
Xanthine oxidoreductase-IN-4 is an orally active xanthine oxidoreductase (XOR) inhibitor. Xanthine oxidoreductase-IN-4 has inhibitory activity against XOR with an IC50 value of 29.3 nM. Xanthine oxidoreductase-IN-4 can be used for the research of hyperuricemia[1]. | [in vivo]
Xanthine oxidoreductase-IN-4 (Compound IIIc) (oral; 5 mg/kg) shows a significant hypouricemia effect in a potassium oxazinate/hypoxanthine-induced model of acute hyperuricemia[1]. | Animal Model: | Mice acute hyperuricemia model[1] | | Dosage: | 5 mg/kg | | Administration: | Oral | | Result: | Reduced serum levels of uric acid significantly from 4 h after administration. |
| [References]
[1] Wen Peng, et al. Design, synthesis, and evaluation of tricyclic compounds containing phenyl-tetrazole as XOR inhibitors. Eur J Med Chem. 2022 Nov 28;246:114947. DOI:10.1016/j.ejmech.2022.114947 |
|
|